产品
编 号：F395954
分子式：C21H27N
分子量：293.45
分子式：C21H27N
分子量：293.45
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 57982-78-2
产品详情
生物活性：
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease.
体内研究：
Budipine (s.c., 30 μg/24 h, 11 days) is a substrate of P-glycoprotein (P-gp) and is actively transported out of the brain through the blood–brain barrier back into the blood plasma.Animal Model:Male abcblab(-/-) mice Male abcblab(-/-) mice (n=8, weight 29.0 g) and FVB/N wild-type mice (n =8, weight 28.0 g)
Dosage:30 μg(Budipine is dissolved in 0.9% sodium chloride and 0.5% ethanol)
Administration:subcutaneous injections, continuously delivered 30 μg over 24 h, 11 days
Result:Increased the cerebrum concentration for 3.1 times high in knock-out mice after an 11-day continuous administration.Showed no significant differences in plasma, spleen, kidney and liver.
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease.
体内研究：
Budipine (s.c., 30 μg/24 h, 11 days) is a substrate of P-glycoprotein (P-gp) and is actively transported out of the brain through the blood–brain barrier back into the blood plasma.Animal Model:Male abcblab(-/-) mice Male abcblab(-/-) mice (n=8, weight 29.0 g) and FVB/N wild-type mice (n =8, weight 28.0 g)
Dosage:30 μg(Budipine is dissolved in 0.9% sodium chloride and 0.5% ethanol)
Administration:subcutaneous injections, continuously delivered 30 μg over 24 h, 11 days
Result:Increased the cerebrum concentration for 3.1 times high in knock-out mice after an 11-day continuous administration.Showed no significant differences in plasma, spleen, kidney and liver.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备